Hofseth BioCare ASA (HOFBF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 259.91 Million USD | 3453.76% |
| 2022 | 7.31 Million NOK | -27.65% |
| 2021 | 10.1 Million NOK | 220.23% |
| 2020 | -8.4 Million NOK | -294.89% |
| 2019 | 4.31 Million NOK | -66.44% |
| 2018 | 12.85 Million NOK | -67.33% |
| 2017 | 39.35 Million NOK | -33.61% |
| 2016 | 59.28 Million NOK | -16.67% |
| 2015 | 71.14 Million NOK | -27.86% |
| 2014 | 98.62 Million NOK | 5.46% |
| 2013 | 93.51 Million NOK | 39.51% |
| 2012 | 67.03 Million NOK | 1118.1% |
| 2011 | 5.5 Million NOK | -7.03% |
| 2010 | 5.91 Million NOK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 13.49 Million USD | 2.66% |
| 2024 Q1 | 12.97 Million USD | 24.39% |
| 2023 Q2 | 7.87 Million USD | 5.53% |
| 2023 Q3 | 7.64 Million USD | -2.91% |
| 2023 Q4 | 11.08 Million USD | 44.99% |
| 2023 Q1 | 7.46 Million USD | 2.02% |
| 2023 FY | 259.91 Million USD | 3453.76% |
| 2022 Q4 | 7.31 Million NOK | 32.05% |
| 2022 Q1 | 11.92 Million NOK | 17.95% |
| 2022 Q2 | 15.53 Million NOK | 30.26% |
| 2022 Q3 | 5.53 Million NOK | -64.34% |
| 2022 FY | 7.31 Million NOK | -27.65% |
| 2021 Q1 | -4.78 Million NOK | 93.15% |
| 2021 FY | 10.1 Million NOK | 220.23% |
| 2021 Q2 | 1.85 Million NOK | 138.71% |
| 2021 Q4 | 10.1 Million NOK | 61.99% |
| 2021 Q3 | 6.24 Million NOK | 237.02% |
| 2020 FY | -8.4 Million NOK | -294.89% |
| 2020 Q1 | 47.15 Million NOK | 11.66% |
| 2020 Q2 | 83.07 Million NOK | 76.18% |
| 2020 Q3 | 118.55 Million NOK | 42.7% |
| 2020 Q4 | -69.86 Million NOK | -158.94% |
| 2019 Q4 | 42.23 Million NOK | 48.64% |
| 2019 Q1 | 89.24 Million NOK | 594.12% |
| 2019 Q2 | 101.62 Million NOK | 13.88% |
| 2019 FY | 4.31 Million NOK | -66.44% |
| 2019 Q3 | 28.41 Million NOK | -72.04% |
| 2018 Q3 | -1.88 Million NOK | -102.94% |
| 2018 Q2 | 64.01 Million NOK | 51.57% |
| 2018 Q1 | 42.23 Million NOK | 7.3% |
| 2018 FY | 12.85 Million NOK | -67.33% |
| 2018 Q4 | 12.85 Million NOK | 783.52% |
| 2017 Q4 | 39.35 Million NOK | 269.53% |
| 2017 Q3 | 10.65 Million NOK | -28.67% |
| 2017 Q2 | 14.93 Million NOK | 35654.76% |
| 2017 FY | 39.35 Million NOK | -33.61% |
| 2017 Q1 | -42 Thousand NOK | -100.07% |
| 2016 Q4 | 59.28 Million NOK | 31.78% |
| 2016 FY | 59.28 Million NOK | -16.67% |
| 2016 Q3 | 44.99 Million NOK | -62.88% |
| 2016 Q2 | 121.2 Million NOK | 26.02% |
| 2016 Q1 | 96.18 Million NOK | 35.19% |
| 2015 Q2 | 92.37 Million NOK | -12.73% |
| 2015 FY | 71.14 Million NOK | -27.86% |
| 2015 Q3 | 110.92 Million NOK | 20.08% |
| 2015 Q1 | 105.84 Million NOK | 7.32% |
| 2015 Q4 | 71.14 Million NOK | -35.86% |
| 2014 Q1 | 97.54 Million NOK | 4.31% |
| 2014 FY | 98.62 Million NOK | 5.46% |
| 2014 Q4 | 98.62 Million NOK | 14.87% |
| 2014 Q2 | 80.52 Million NOK | -17.45% |
| 2014 Q3 | 85.85 Million NOK | 6.63% |
| 2013 Q4 | 93.51 Million NOK | 9.95% |
| 2013 Q3 | 85.04 Million NOK | 13.9% |
| 2013 FY | 93.51 Million NOK | 39.51% |
| 2013 Q2 | 74.67 Million NOK | -17.1% |
| 2013 Q1 | 90.07 Million NOK | 34.38% |
| 2012 Q1 | 18.69 Million NOK | 239.8% |
| 2012 FY | 67.03 Million NOK | 1118.1% |
| 2012 Q2 | 31.55 Million NOK | 68.78% |
| 2012 Q4 | 67.03 Million NOK | 18.8% |
| 2012 Q3 | 56.42 Million NOK | 78.79% |
| 2011 FY | 5.5 Million NOK | -7.03% |
| 2011 Q3 | 21 Million NOK | 0.0% |
| 2011 Q4 | 5.5 Million NOK | -73.8% |
| 2010 FY | 5.91 Million NOK | 0.0% |
| 2010 Q4 | 5.91 Million NOK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -1548.912% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -6211.716% |
| SQZ Biotechnologies Company | -36.23 Million USD | 817.253% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -507.384% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 4222.722% |
| Mesoblast Limited | 55.85 Million USD | -365.317% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -27932.994% |
| Genus plc | 190.6 Million USD | -36.368% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -11525.113% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -21312.025% |
| Marizyme, Inc. | 18.56 Million USD | -1299.739% |
| ContraFect Corporation | -6.02 Million USD | 4413.276% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -38123.235% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -192948.077% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -22395.368% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -11491.926% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -4624.153% |
| MultiCell Technologies, Inc. | 90.04 USD | -288669380.231% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 35512.233% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -1907.709% |
| EV Biologics, Inc. | 1.36 Million USD | -18900.257% |
| Q BioMed Inc. | 4.06 Million USD | -6301.909% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -750.684% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -41663.02% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -25692.783% |
| Biomind Labs Inc. | 711.4 Thousand USD | -36436.023% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | -136.711% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -1929.564% |
| Skye Bioscience, Inc. | -5.72 Million USD | 4642.918% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -30114.556% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -185815.997% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -4501.646% |
| IMV Inc. | 7.67 Million USD | -3288.531% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1308190.129% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -11703.826% |
| GB Sciences, Inc. | 1.74 Million USD | -14775.272% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 141522.726% |
| HST Global, Inc. | 96.79 Thousand USD | -268429.749% |
| CSL Limited | 10.52 Billion USD | 97.531% |
| Halberd Corporation | 144.72 Thousand USD | -179499.367% |
| Enzolytics Inc. | 981.65 Thousand USD | -26377.503% |
| Resverlogix Corp. | 6.45 Million USD | -3929.112% |
| Affymax, Inc. | -5.59 Million USD | 4743.881% |
| SYBLEU INC | 473.71 Thousand USD | -54768.127% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 38715.696% |
| argenx SE | -2.02 Billion USD | 112.811% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -498.421% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 652.876% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -9495.974% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 3040.278% |
| AVAX Technologies, Inc. | -5.9 Million USD | 4502.997% |
| Zenith Capital Corp. | 10.06 Thousand USD | -2582551.033% |
| Genscript Biotech Corporation | -1.06 Billion USD | 124.49% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -129578.894% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -10793.307% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -157896.219% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -329.292% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -12899.852% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 10213.415% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -72157.652% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -1181.9% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1419021.28% |
| BioStem Technologies, Inc. | 4.47 Million USD | -5712.106% |
| ONE Bio Corp. | 9.04 Million USD | -2775.188% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -129049.234% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 19841168.702% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -125941.015% |
| Agentix Corp. | 37.63 Thousand USD | -690601.815% |
| LadRx Corporation | -2.03 Million USD | 12863.17% |
| Cell Source, Inc. | 9.23 Million USD | -2715.412% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1273708.389% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -40821.207% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -40821.207% |
| NovAccess Global Inc. | 2.17 Million USD | -11831.245% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -3575.845% |
| Itoco Inc. | 228.3 Thousand USD | -113746.828% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -191031.636% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -5143.454% |
| Kadimastem Ltd | -253.1 Thousand USD | 102792.985% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -64580.514% |
| CytoDyn Inc. | 20.26 Million USD | -1182.786% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 40172897.527% |
| Mobile Lads Corp. | 484.23 Thousand USD | -53576.337% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 2804464.104% |
| Qrons Inc. | 351.42 Thousand USD | -73860.737% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -3272.929% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 104225.471% |
| Rebus Holdings, Inc. | 305 Thousand USD | -85119.016% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -5731.652% |
| International Stem Cell Corporation | 2.59 Million USD | -9935.444% |
| Bioxytran, Inc. | 1.89 Million USD | -13587.718% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -416348.496% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -11817.924% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -7468.957% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -2938.91% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -33541.683% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 20893.44% |
| Neutra Corp. | 52.18 Thousand USD | -497951.239% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 10542.668% |
| PureTech Health plc | -167.19 Million USD | 255.456% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 106228.832% |
| IXICO plc | -4.44 Million USD | 5947.967% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -1866.246% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -373.862% |
| CSL Limited | 10.52 Billion USD | 97.531% |
| Cellectis S.A. | -43.81 Million USD | 693.165% |